**Supplementary Table 1 – Characteristics of patients with ARD and CG at 6 weeks after 2nd Sinovac-CoronaVac (D69)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ARD****(n=828)** | **CG****(n=207)** | ***p* value** |
| **Demographics** |  |  |  |
|  **Current age, years**  | 51 (41-60) | 51 (42-60) | 0.898 |
| **Age ≥ 60 years** | 213 (25.7) | 54 (26.1) | 0.915 |
|  **Male sex** | 204 (24.6) | 51 (24.6) | >0.999 |
| **Caucasian race** | 425 (51.3) | 95 (45.9) | 0.163 |
| **ARD** |  |  |  |
| **Rheumatoid arthritis** | 228 (27.5) | - | - |
| **Axial spondyloarthritis** | 196 (23.7) | - | - |
| **Systemic lupus erythematosus** | 206 (24.9) | - | - |
| **Primary vasculitis** | 51 (6.2) | - | - |
| **Systemic sclerosis** | 36 (4.3) | - | - |
| **Primary Sjögren syndrome** | 36 (4.3) | - | - |
| **Idiopathic inflammatory myopathy** | 40 (4.8) | - | - |
| **CURRENT THERAPY**  |  |  |  |
| **Prednisone** | 302 (36.5) | - | - |
| **Prednisone dose, mg**  | 5 (5-40) | - | - |
| **Prednisone ≥ 10mg/day** | 116 (14.0) |  |  |
| **Prednisone ≥ 20mg/day** | 27 (3.3) | - | - |
| **Hydroxychloroquine** | 239 (28.9) | - | - |
| **Sulfasalazine** | 72 (8.7) | - | - |
| **Immunosuppressive drugs** | 513 (62.0) | - | - |
| **Methotrexate** | 209 (25.2) | - | - |
| **Leflunomide** | 115 (13.9 | - | - |
| **Mycophenolate mofetil** | 109 (13.2) | - | - |
| **Azathioprine** | 90 (10.9) | - | - |
| **Tofacitinib** | 20 (2.4) | - | - |
| **Cyclophosphamide** | 6 (0.7) | - | - |
| **Tacrolimus** | 10 (1.2) | - | - |
| **Cyclosporine** | 9 (1.1) | - | - |
| **Biologic therapy** | 296 (35.7) | - | - |
| **TNF inhibitor** | 126 (15.2) | - | - |
| **Abatacept** | 43 (5.2) | - | - |
| **Tocilizumab** | 46 (5.6) | - | - |
| **Belimumab** | 26 (3.1) | - | - |
| **Secukinumab** | 34 (4.1) | - | - |
| **Rituximab** | 17 (2.1) | - | - |
| **Ustekinumab** | 4 (0.5) | - | - |

ARD – autoimmune rheumatic diseases; CG – control group.

Results are expressed in medians (interquartile range) and n (%). Continuous data were compared using Mann-Whitney test, and categorical variables with the chi-square or Fisher's exact tests, as appropriate, always as two-sided analyses.